Hematology Oncology Research

Publications

Researchers within the UCLA Division of Hematology-Oncology routinely disseminate the findings of their impactful work through publications in top-tier journals. Keep up with their latest articles here.

August 2026

  1. Rugo HS, Schmid P, Cortes J, Takano T, Fasching PA, Park YH, Bianchini G, Franco SX, Villarreal-Garza C, Tredan O, Yin Y, Barroso-Sousa R, Peng X, Malhotra U, Smith KL, Bardia A. TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10. Future Oncol. 2026 Aug;22(18):2121-2129. doi: 10.1080/14796694.2026.2701483. Epub 2026 Jul 31. PMID: 42535874.
  2. Sanchez Jimenez A, Hirt C, Anand S, Tsai S, Ma J. Newly Diagnosed VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome in a Patient Presenting With Legionella Pneumonia. Cureus. 2026 Jun 30;18(6):e111837. doi: 10.7759/cureus.111837. PMID: 42535209; PMCID: PMC13423577.
  3. Campos R, Caldera F, Carrico J, Cochrane C, Eltoukhy N, Huang C, Kneller S, Rutland C, Slovis J. Women and Herpes Zoster in the United States: Risk and Prevention Management-A Narrative Review. Womens Health Rep (New Rochelle). 2026 May 21;7:26884844261445552. doi: 10.1177/26884844261445552. PMID: 42539376; PMCID: PMC13420991.
  4. Castillo DR, Shah P, Tai D, Guo M, Hazeltine M, Guzman S, Park D, Mannan R, Xing Y, Brar G, Raoof M, Eng C, Wu S. Early-Onset Gastric Cancer as a High-Risk Disease Entity in the United States: Clinicopathologic Features, Regional Variation, and Outcomes. Cancer Med. 2026 Aug;15(8):e72154. doi: 10.1002/cam4.72154. PMID: 42538623; PMCID: PMC13428078.
  5. Shan NL, Balinda H, Dai J, Wang Y, Lin HK, Marczyk M, Espinoza Campos G, Umlauf S, McDermott MSJ, Colorado I, Lang SM, Surovtseva YV, Feinman R, Slamon DJ, Blenman KRM, Yan Q, Muthusamy V, Brenner AJ, Pusztai L. Inhibition of Acetyl-CoA-carboxylase induces endoplasmic reticulum stress and augments the efficacy of anti-cancer therapies. Clin Cancer Res. 2026 Aug 3. doi: 10.1158/1078-0432.CCR-26-1028. Epub ahead of print. PMID: 42545737.
  6. Choueiri TK, Merchán J, Patnaik A, Drakaki A, Rini BI, Rha SY, Lee JL, Ornstein MC, Kumar R, Hwang C, Shao Y, Park SH, Barata PC, McGregor BA, Foster P, Chen J, Eisen M, Cole H, Weeder B, Guan Y, Singh J, Kaplan A, Cho S, Markus R, Kabbarah O, McKay RR. Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer. Nature. 2026 Aug 4. doi: 10.1038/s41586-026-10958-x. Epub ahead of print. Erratum for: Nature. 2026 Jul 1. doi: 10.1038/s41586-026-10718-x. PMID: 42552389.
  7. ElHarouni D, Al-Jazrawe M, Choi S, Dede M, Hinoue T, Misek SA, Noh H, Zanella L, Tseng YY, Francies HE, Plenker D, Kyi CW, Perez-Mayoral J, Stine MJ, Tonsing-Carter E, Agarwal R, Zenklusen JC, Clinton JM, Shelton JM, Chu TR, Hooper WF, Loinaz X, Keskula P, Tagle J, Kuhlers PC, Tercan B, Boj SF, Vasciaveo A, Tomassoni L, Crawford JM, Walsh S, Sinai C, Bhatia S, Sridevi P, Patel H, Cerone MA; HCMI Network; Ellrott K, Kuo CJ, Elemento O, Beyaz S, Corbo V, Spector DL, Beroukhim R, Ferguson ML, Cherniack AD, Laird PW, Robine N, McPherson A, Hoadley KA, Garnett MJ, Tuveson DA, Califano A, Spellman PT, Ligon KL, Gerhard DS, Staudt LM, Boehm JS. A compendium of next-generation patient-derived models for diverse cancers. Nature. 2026 Aug 5. doi: 10.1038/s41586-026-10806-y. Epub ahead of print. PMID: 42557316.
  8. Singal AG, Agopian VG, Dawson LA, El-Khoueiry A, Finn RS, Halazun K, Heimbach JK, Kelley RK, Kim E, Kulik L, Mehta N, Mendiratta-Lala M, Meyer J, Parikh ND, Pillai A, Salem R, Sapisochin G, Tabrizian P, Yopp A, Yarchoan M; HCC-Live Steering Committee. BEACON-HCC: Best evidence and north american consensus on treatment allocation for hepatocellular carcinoma. Hepatology. 2026 Aug 7. doi: 10.1097/HEP.0000000000001834. Epub ahead of print. PMID: 42565685.
  9. Hsu JH, Shi Y, Frost P, Yan H, Hoang B, Sharma S, Gera J, Lichtenstein A. Editorial Expression of Concern: Interleukin-6 activates phosphoinositol-3' kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways. Oncogene. 2026 Aug 10. doi: 10.1038/s41388-026-03952-0. Epub ahead of print. PMID: 42575983.
  10. Margolis S, Guirguis AN, Lee C, Smith S, LeVee A, Lipsyc-Sharf MD, Bardia A, Sedrak MS. Patient-reported outcomes in clinical trials leading to breast cancer drug approvals: are we making them count? Breast Cancer Res Treat. 2026 Aug 10;218(3):35. doi: 10.1007/s10549-026-08051-y. PMID: 42573832.
  11. Schiller G, Leer LR. Medical Societies in the United States: History, Purpose, Challenge, and Future Directions. Cureus. 2026 Jul 10;18(7):e112407. doi: 10.7759/cureus.112407. PMID: 42572655; PMCID: PMC13453329.
  12. Ribas A, Robert C, Schadendorf D, Long GV, Tawbi H, Flaherty K, Ascierto PA, Nathan P, Rutkowski P, Leonov OV, Lorigan P, Prey S, Saponara M, Arance A, Gaudy-Marqueste C, Stroyakovskiy D, Lebbe C, Maio M, Del Vecchio M, Boghikian PS, Gutzmer R, Depenni R, Miskic M, Russo M, Dummer R. COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma. J Clin Oncol. 2026 Aug 12:JCO2600528. doi: 10.1200/JCO-26-00528. Epub ahead of print. PMID: 42585631.
  13. Wise-Draper TM, Robert C, Wong MK, Middleton MR, Sacco JJ, In GK, Muñoz Couselo E, Schadendorf D, Beasley GM, Niu J, Chmielowski B, Milhem MM, Bowles TL, Tsai KK, Samson A, Harrington KJ, Lebbé C, Gaudy-Marqueste C, Zhu J, Paratala B, Hou JW, Xynos K, Clack A, Coffin RS, Bommareddy PK. Biodistribution, shedding, and transmissibility of vusolimogene oderparepvec (RP1). Front Oncol. 2026 Jul 28;16:1798502. doi: 10.3389/fonc.2026.1798502. PMID: 42582160; PMCID: PMC13457113.
  14. Galanina N, Iqbal M, Tomassetti S, Nousome D, Tin A, Gillespie CP, Youngberg H, Miller P, Malhotra M, Widden H, Rodriguez A, Liu MC, Narkhede M, William BM. ctDNA for MRD assessment is prognostic and predictive in newly diagnosed and relapsed/refractory lymphoma. Blood Neoplasia. 2026 May 26;3(3):100250. doi: 10.1016/j.bneo.2026.100250. PMID: 42603998; PMCID: PMC13476554.
  15. Baclig NV, Chengappa M, Soliman AJ, Jacob S, LeVee A, Fisch S, Face C, Chaudhry S, Idossa D, Poonacha T, Huppert L, Quintal L, Melisko M, Majure M, Tsai K, Kordic A, Chien J, Mortimer J, Rugo HS, Lechner MG, Blaes A, McCann KE. Incidence, Risk Factors, and Survival Implications of Immune-Related Adverse Events in Patients With Metastatic Breast Cancer. Clin Breast Cancer. 2026 Jul 20;26(9):91-100. doi: 10.1016/j.clbc.2026.07.026. Epub ahead of print. PMID: 42607491.
  16. Damron LF, Kinney L, Kathuria-Prakash N, Iliopoulos M, Stefanoudakis D, Lopez LP, Sakkal M, Khanlou N, Hart SD, Moatamed NA, Palaskas NJ, Drakaki A. A Case Report of a 64-Year-Old Man With Urothelial Carcinoma With Brain and Leptomeningeal Metastases Treated With Intrathecal Methotrexate as Part of Multimodal Management. Am J Case Rep. 2026 Aug 17;27:e951572. doi: 10.12659/AJCR.951572. PMID: 42607018.
  17. Bondariyan N, Patel M, Shah P, Park D, Dermarderosian A, Arfaie S, Mashayekhi M, Dashtipour K, Akhtari M. Choreiform Movements and Pachymeningeal Enhancement in an Elderly Patient With Abnormal Blood Counts: A Case Report and Review of Literature. J Investig Med High Impact Case Rep. 2026 Jan-Dec;14:23247096261478912. doi: 10.1177/23247096261478912. Epub 2026 Aug 17. PMID: 42606347.
  18. Sidhu N, Le BM, Doan EL, Dao KT, Montana W. A Case of Gastrointestinal Krukenberg Tumor Initially Suspected as Primary Ovarian Cancer and the Implications for Management. Cureus. 2026 Jul 16;18(7):e112822. doi: 10.7759/cureus.112822. PMID: 42605250; PMCID: PMC13477497.
  19. Mar N, Cabral MY, Go J, Kaakour D, Dwabe S, Seyedin SN, Drakaki A. Real-World Toxicity and Efficacy Profile of Enfortumab Vedotin With or Without Pembrolizumab in Ultra-Elderly Patients With Advanced Urothelial Carcinoma. JCO Oncol Pract. 2026 Aug 18:OP2600527. doi: 10.1200/OP-26-00527. Epub ahead of print. PMID: 42612175.
  20. Kim DH, Keshavarz P, Tibbe TD, Suh RD, Abtin F, Genshaft SJ, Drakaki A, Shuch BM, Pantuck AJ, Lu DS, Raman SS. Long-Term Survival After Percutaneous Image-Guided Thermal Ablation of Oligometastatic Renal Cell Carcinoma. J Vasc Interv Radiol. 2026 Aug 19:109040. doi: 10.1016/j.jvir.2026.109040. Epub ahead of print. PMID: 42617973.
  21. Saba NF, Posner M, Harrington K, Neupane P, Rezaee R, Nenclares P, Jimeno A, Denker AE, MacIntyre S, Makris L, Wong D. Danvatirsen plus pembrolizumab versus pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma (PEMDA-HN): a randomized, phase 2 trial. Clin Cancer Res. 2026 Aug 19. doi: 10.1158/1078-0432.CCR-26-0819. Epub ahead of print. PMID: 42615600.
  22. Falchi L, Offner F, de Vos S, Brody JD, Morillo D, Linton K, Snauwaert S, Roost Clausen M, Karimi YH, Thieblemont C, Vitolo U, Leslie LA, Narkhede MS, Córdoba R, Oki T, Wielgos-Bonvallet M, Khoshdeli M, Hao Y, Archer K, Risum M, Belada D. Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial. Blood. 2026 Aug 11:blood.2026033839. doi: 10.1182/blood.2026033839. Epub ahead of print. PMID: 42622258.
  23. Silverstein J, Alomaja O, Chatram D, Hajiabbasi M, Shachar E, Tseng CH, Thaker S, Bardia A, Karlan B, Hendrickson AW, Konecny GE. Real-world clinical outcomes of Trastuzumab Deruxtecan in HER2-expressing ovarian and endometrial Cancer. Gynecol Oncol Rep. 2026 Aug 12;66:102183. doi: 10.1016/j.gore.2026.102183. PMID: 42621866; PMCID: PMC13487597.
  24. Oliai CH, Gandhi A, Hoeg RT, Muffly L, Srour SA, Mehta RS, Waller EK, Lowsky R, Patel SS, Dholaria B, Pantin J, Salhotra A, McGuirk JP, Gomez-Arteaga A, Faramand R, Tamari R, Holter-Chakrabarty J, Hamilton BK, Jimenez AMJ, Murray J, Killian MS, Pavlova A, Fernhoff NB, McClellan JS, Abedi M, Negrin RS, Meyer EH. Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients. Transplant Cell Ther. 2026 Aug 21:S2666-6367(26)00678-0. doi: 10.1016/j.jtct.2026.08.037. Epub ahead of print. PMID: 42628650.
  25. Chan BL, Iguh C, Hwang A, Huang C. Metastatic Cutaneous Apocrine Carcinoma: Diagnostic and Therapeutic Challenges in a Rare Malignancy. Cureus. 2026 Jul 21;18(7):e113113. doi: 10.7759/cureus.113113. PMID: 42626471; PMCID: PMC13493036.
  26. Waissengrin B, O'Connor K, Shirazipour CH, Ivan FA, Reckamp KL, Gonzalez-Hernandez G, Figueiredo JC. Insights on supplement use during cancer care from online Reddit conversations. BMC Complement Med Ther. 2026 Jul 25;26(1):256. doi: 10.1186/s12906-026-05411-5. PMID: 42632897; PMCID: PMC13499959.
  27. Brierley-Green E, Duggirala N, McCann KE, Callahan R, Bardia A, Lipsyc-Sharf M. Novel Endocrine Therapies: Current Status and Future Directions. Clin Breast Cancer. 2026 Aug 22;26(9):127-136. doi: 10.1016/j.clbc.2026.07.010. Epub ahead of print. PMID: 42632230.
  28. Le X, Passaro A, Zhao Y, Huang Y, Laskin J, Rodriguez-Abreu D, Calles A, Bazhenova L, Lo Russo G, Leighl NB, Cappuzzo F, Girard N, Popat S, Fang W, Luo Y, Li W, He Z, Zhao H, Li M, Song Q, Zhao H, El Darsa H, Monnet I, Cobo Dols M, García Campelo R, Jotte R, Berz D, Spira A, Pérol M, Nagasaka M, West H, Styles L, Li J, Clow F, Goldman J, Zhang L. Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2026 Sep;27(9):1094-1109. doi: 10.1016/S1470-2045(26)00282-2. PMID: 42636833.
  29. Rugo HS, Tolaney SM, Chan N, Borges G, Yerushalmi R, Sharifi MN, McHayleh W, Beck T, Vidula N, Hamilton E, Rinn KJ, O'Shaughnessy J, Curigliano G, Cortés J, Garcia-Fructuoso I, Aftimos P, Bermejo de Las Heras B, Tolosa P, Yuan Y, Valero V, Lipsyc-Sharf M, Muñoz Romero P, Koraichi Auriol F, Paoli A, Crozier JA, Wasserman T, Kaklamani V. Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE. Clin Cancer Res. 2026 Aug 24. doi: 10.1158/1078-0432.CCR-26-1816. Epub ahead of print. PMID: 42635598.
  30. Shachar EK, Silverstein J, Gornbein J, Salani R, Karlan BY, Chase DM. Actionable biomarker co-expression in advanced ovarian cancer: folate receptor alpha expression and related markers. Int J Gynecol Cancer. 2026 Aug 6:104893. doi: 10.1016/j.ijgc.2026.104893. Epub ahead of print. PMID: 42642279.
  31. Smith CE, Sammons SL, Minami CA, Sedrak MS, Magnuson A, O'Connor T, Hshieh TT, Smith S, Ruderman K, Bak K, Lin NU, Freedman RA. Systemic Therapy Considerations in Older Adults With Early-Stage Breast Cancer: A Review. JAMA Oncol. 2026 Aug 27. doi: 10.1001/jamaoncol.2026.3121. Epub ahead of print. PMID: 42658515.
  32. Rashba GB, Kaplan L, Bolos D, Baltayan A, Backer S. Urgent Chemotherapy for Aggressive Metastatic Neuroendocrine Cancer With Impending Hepatic Failure: A Case Report. Cureus. 2026 Jul 29;18(7):e113596. doi: 10.7759/cureus.113596. PMID: 42666762; PMCID: PMC13524009.
  33. Ramesh K, Hui G, Shodiya M, Palaskas NJ. Unmasking Factor XIII Deficiency: Recurrent Intracranial Hemorrhage Despite Normal Coagulation Studies. Cureus. 2026 Jul 29;18(7):e113621. doi: 10.7759/cureus.113621. PMID: 42669027; PMCID: PMC13525910.
View the full list of Hematology Oncology publications